{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T04:12:39Z","timestamp":1788581559004,"version":"build-2803163510"},"reference-count":15,"publisher":"Japanese Society of Internal Medicine","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,9,1]]},"DOI":"10.2169\/internalmedicine.6829-25","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T22:08:32Z","timestamp":1768428512000},"page":"2380-2383","source":"Crossref","is-referenced-by-count":1,"title":["Mucous Membrane Pemphigoid during CPX-351 Therapy Successfully Treated with Corticosteroids"],"prefix":"10.2169","volume":"65","author":[{"given":"Masahiro","family":"Akimoto","sequence":"first","affiliation":[{"name":"Department of Hematology, Kanagawa Cancer Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Matsuki","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery, Kanagawa Cancer Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiki","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kanagawa Cancer Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Katsuki","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kanagawa Cancer Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayoshi","family":"Tachibana","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kanagawa Cancer Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatsugu","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kanagawa Cancer Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Zeng X, Jin X, Zhong L, et al. Difficult and complicated oral ulceration: an expert consensus guideline for diagnosis. Int J Oral Sci 14: 28, 2022.","DOI":"10.1038\/s41368-022-00178-0"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Lee YH, Hong J, Kim I, Choi Y, Park HK. Prospective evaluation of clinical symptoms of chemotherapy-induced oral mucositis in adult patients with acute leukemia: a preliminary study. Clin Exp Dent Res 6: 90-99, 2020.","DOI":"10.1002\/cre2.253"},{"key":"3","first-page":"310","volume":"7","author":"S Biswal","year":"2013","unstructured":"3. Biswal S, Godnaik C. Incidence and management of infections in patients with acute leukemia following chemotherapy in general wards. Ecancermedicalscience 7: 310, 2013.","journal-title":"ecancermedicalscience","ISSN":"https:\/\/id.crossref.org\/issn\/1754-6605","issn-type":"print"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Tzogani K, Penttil\u00e4 K, Lapvetel\u00e4inen T, et al. EMA review of daunorubicin and cytarabine encapsulated in liposomes (Vyxeos, CPX-351) for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukemia or acute myeloid leukemia with myelodysplasia-related changes. Oncologist 25: e1414-e1420, 2020.","DOI":"10.1634\/theoncologist.2019-0785"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Lancet JE, Cortes JE, Hogge DE, et al. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine\/daunorubicin, vs cytarabine\/daunorubicin in older adults with untreated AML. Blood 123: 3239-3246, 2014.","DOI":"10.1182\/blood-2013-12-540971"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Usuki K, Miyamoto T, Yamauchi T, et al.; The Study Group for NS-87\/CPX-351. A phase 1\/2 study of NS-87\/CPX-351 (cytarabine and daunorubicin liposome) in Japanese patients with high-risk acute myeloid leukemia. Int J Hematol 119: 647-659, 2024.","DOI":"10.1007\/s12185-024-03733-z"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Hofmann SC, G\u00fcnther C, B\u00f6ckle BC, et al. S2k Guideline for the diagnosis and treatment of mucous membrane pemphigoid. J Dtsch Dermatol Ges  20: 1530-1550, 2022.","DOI":"10.1111\/ddg.14905"},{"key":"8","unstructured":"8. Fujita N, Yamashita T, Abe F, et al. [Refractory esophageal stricture of esophageal mucous membrane pemphigoid after allogeneic hematopoietic stem cell transplantation]. Rinsho Ketsueki (Jpn J Clin Hematol) 64: 107-112, 2023 (in Japanese)."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Chiche E, Rahm\u00e9 R, Bertoli S, et al. Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort. Blood Adv 5: 176-184, 2021.","DOI":"10.1182\/bloodadvances.2020003159"},{"key":"10","unstructured":"10. Hama N, Aoki S, Chen CB, et al. Recent progress in Stevens-Johnson syndrome\/toxic epidermal necrolysis: diagnostic criteria, pathogenesis and treatment. Br J Dermatol 192: 9-18, 2024."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Petruzzi M, Tampoia M, Serpico R, et al. Evaluation of BP180-NC16A ELISA in exclusive oral pemphigoid diagnosis. A comparative study. Oral Dis 27: 525-531, 2021.","DOI":"10.1111\/odi.13574"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Schmidt E, Rashid H, Marzano AV, et al. European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology - Part II. J Eur Acad Dermatol Venereol 35: 1926-1948, 2021.","DOI":"10.1111\/jdv.17395"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Iovene FR, Santinelli E, Armiento D, et al. Acute myeloid leukemia with paraneoplastic pemphigus successfully treated with a personalized antileukemic and immunosuppressive strategy. Ann Hematol 103: 2545-2549, 2024.","DOI":"10.1007\/s00277-024-05804-x"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Lloyd-Lavery A, Chi CC, Wojnarowska F, Taghipour K. The associations between bullous pemphigoid and drug use: a UK case-control study. JAMA Dermatol 149: 58-62, 2013.","DOI":"10.1001\/2013.jamadermatol.376"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. B\u00e9n\u00e9 J, Moulis G, Bennani I, et al.; the French Association of Regional PharmacoVigilance Centres. Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French Pharmacovigilance Database. Br J Dermatol 175: 296-301, 2016.","DOI":"10.1111\/bjd.14601"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/17\/65_6829-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T03:31:27Z","timestamp":1788579087000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/17\/65_6829-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":15,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6829-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"article-number":"6829-25"}}